Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00416650 · ClinicalTrials.gov registry record · Phase 2

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

A Phase 2 study of Lung Cancer, sponsored by Vanderbilt-Ingram Cancer Center.

Completed
Registry status
Phase 2
Development phase
16
Enrollment target
4
Study locations

NCT00416650 is a Phase 2 study of Lung Cancer that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 16 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00416650, a Phase 2 study of Lung Cancer, has completed, sponsored by Vanderbilt-Ingram Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
16 participants
Enrollment target
4
Study locations

Study Summary

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with advanced non-small cell lung cancer.

Conditions Studied

Lung Cancer

Interventions

  • DRUG erlotinib hydrochloride

Study Locations (4)

Illinois

  • Northwestern Memorial Hospital - Chicago

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Tennessee

  • Vanderbilt-Ingram Cancer Center - Nashville

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2002-07
Est. Completion 2013-03
Phase Phase 2

Sponsor

Vanderbilt-Ingram Cancer Center

189 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00416650

The ClinicalTrials.gov registry entry for NCT00416650 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which erlotinib hydrochloride is the first listed.

NCT00416650 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Illinois, New York, Tennessee.

Frequently Asked Questions

What is clinical trial NCT00416650 about?

NCT00416650 is a clinical study titled "Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer". RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with advanced non-small cell lung cancer.

What is the current status of trial NCT00416650?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2002-07. Estimated completion is 2013-03.

What conditions does trial NCT00416650 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT00416650?

The interventions under investigation include: erlotinib hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00416650?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00416650 being conducted?

This trial has 4 study locations across Illinois, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.